- Home
- TXO vs ORIC Comparison
TXO vs ORIC Comparison
Compare TXO & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TXO | ORIC |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 720.9M | 861.3M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TXO | ORIC |
|---|---|---|
| Price | $13.23 | $11.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $20.50 | $19.73 |
| AVG Volume (30 Days) | 132.3K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 13.57% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $401,012,000.00 | N/A |
| Revenue This Year | $17.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 41.80 | N/A |
| 52 Week Low | $10.12 | $7.23 |
| 52 Week High | $15.55 | $14.93 |
Technical Indicators
Market Signals| Indicator | TXO | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.02 |
| Support Level | N/A | $9.82 |
| Resistance Level | N/A | $11.24 |
| Average True Range (ATR) | 0.00 | 0.63 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 0.00 | 11.86 |
Price Performance
Historical ComparisonAbout TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America. Its operations focus on enhancing the development and operation of producing properties through its concentration on efficiency and optimizing exploitation of current wells.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.